CombiMatrix Launches Preimplantation Genetic Diagnostic Testing for Single Gene Disorders and Chromosomal Translocations

CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the launch of CombiPGD™ – Preimplantation Genetic Diagnosis (PGD) for single gene disorders and chromosomal translocations.  CombiPGD is a test performed prior to embryo implantation to help identify genetic defects created through in vitro fertilization to prevent certain diseases or disorders from being passed on to the child.
According to the news:

Assisted reproductive technology is typically associated with infertility. However, some fertile couples whose children are at risk for a specific genetic disease or hereditary chromosomal abnormality choose to undergo in vitro fertilization in order to perform PGD. CombiMatrix already offers CombiPGS™, which is a test that may help decrease the rate of implantation failure and miscarriage by allowing physicians to identify and transfer chromosomally normal embryos.

Mark McDonough, President and Chief Executive Officer of CombiMatrix commented:

We are pleased to launch another incremental revenue-producing test in the IVF market that meets a critical clinical need. The CombiPGD test rounds out our IVF test offering, where we also offer PGS testing, parental karyotyping and miscarriage analysis testing. CombiPGD allows couples who are at significant risk of having a child with a serious disorder the opportunity to gain important information about their embryos beforeimplantation with the goal of implanting only those embryos without the disease of concern.

Click here to view the full press release.